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Abstract
Purpose: The purpose of this study was to assess the outcomes in glioblastoma patients treated with hypofractionated 
radiotherapy.
Materials and Methods: We reviewed all glioblastoma patients treated at our specialist cancer centre over 7 and 
a ½ years using hypofractionated radiotherapy (HRT) postoperatively. The HRT regimen was 48 Gy given at 3 Gy/
fractions in 16 fractions. We calculated overall survival using time to event analyses.
Results: A total of 62 patients were identified of whom 44 (71%) were male. The median age of these patients was 
50 years (range: 20–71 years). Eastern Cooperative Oncology Group (ECOG) performance status was 0 in 47 (76%) 
and 1 in 15 (24%) patients. 7 (11%) of the patients underwent gross total resection, 52 (83%) had subtotal resection 
and 3 (5%) had a biopsy only. Response assessment on magnetic resonance imaging at 3-month post-HRT showed that 
14 (22%) patients had regression, 21 (34%) were stable and 22 (35%) had a progressive primary tumour. 5 (8%) patients 
were lost to follow-up. With a median follow-up of 7.8 months, the median overall survival was 9 months. Patients 
with ECOG-0 showed a median survival of 7 months as compared to 6 months for those with ECOG-1. Patients with 
stable or partial response showed a median overall survival of 8 months in comparison to 6 months for those with 
progressive disease. There were no significant differences in median survival based on the extent of surgery. A Cox 
multivariate model confirmed significant correlation of age and response to radiotherapy with survival.
Conclusion: HRT consisting of 48 Gy in 3 weeks can be used for selected glioblastoma patients to reduce the overall 
treatment time of conventional radiotherapy by 35–40% without apparent increased toxicity or decrement in survival 
in a low resource environment.
Key words: Chemoradiation, glioblastoma, hypofractionated radiotherapy, survival
Correspondence: Dr. Sadaf Usman, Departments of Radiation 
Oncology, Shaukat Khanum Memorial Cancer Hospital and Research 
Centre, Lahore, Pakistan.  
Email: sadaf.usmaan@gmail.com
Introduction
Nearly 700,000 new cases of primary brain tumours are 
diagnosed each year.[1] Glioblastoma multiforme (GBM) 
is the most common malignant primary brain tumour 
accounting for 54% of all gliomas. It is also the most 
aggressive variety.[1] The incidence of GBM increases 
after the age of 65 years.[2-4] Treatment of GBM is 
challenging and has limited success. Median survival 
following surgery alone is about 4 months.[2] The benefit 
of post-operative radiotherapy in the treatment of GBM 
has been documented in randomised controlled trials.[5,6] 
However, even with post-operative radiotherapy, the 
median survival time is increased to 9–12 months and 
the 2-year survival rate remains around 10%. The current 
standard of care for young patients with good performance 
status is post-operative chemoradiation followed by 
adjuvant temozolomide. This intense, long and relatively 
expensive course of treatment gives a median survival 
of 14 months, and the overall outcome remains poor. 
Published data have shown that there can be a worsening of 
the quality of life after aggressive treatment schedules.[7-9] 
In patients with GBM, it is desirable to minimise the 
period of treatment and hospitalisation.[8] In developing 
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countries, most patients present at an advanced stage 
and are offered a selective regimen of hypofractionated 
radiotherapy (HRT) rather than the standard regimen. We 
reviewed our data to assess the outcomes amongst GBM 
patients treated with HRT at our institution.
Materials and Methods
This study was carried out in the Department of 
Radiation Oncology at Shaukat Khanum Memorial 
Cancer Hospital and Research Centre (SKMCH and 
RC), a 189-bed specialist cancer centre in Lahore, 
Pakistan. We reviewed the medical records of all GBM 
patients treated at our centre between January 2006 and 
July 2013. All patients had a histologically confirmed 
GBM with Eastern Cooperative Oncology Group 
(ECOG) performance status of 0 or 1. Patients with poor 
performance status (ECOG >1) were excluded from the 
study. The extent of surgical resection was determined by 
reviewing the medical records, as well as pre-operative 
and 4-week post-operative CT or magnetic resonance 
imaging (MRI) brain scans, the histopathology and by 
discussion with the neurosurgeon. Gross total resection 
(GTR) was defined as the radiographic absence on MRI 
of any persistent enhancement. Any MRI enhancement 
thought to represent residual tumour after resection 
was categorised as subtotal resection (STR). HRT was 
started within 4–6 weeks of the surgical procedure. All 
patients were treated using a 6 MV linear accelerator 
and cobalt 60.
The total dose was 48 Gy in 16 fractions of 3 Gy each, 
with five fractions per week given to the enhancing 
tumour (GTV), as delineated with the help of MRI scans. 
Clinical target volume (CTV) was marked with a margin 
of 2.5 cm, including editing from the natural barriers 
(bone). Customised Cerrobend blocks or multileaf 
collimators were used to reduce normal brain irradiation. 
During radiotherapy, dexamethasone (6–12 mg daily) 
was given in combination with a proton-pump inhibitor, 
as well as antiepileptic medication, as needed. After 
completion of treatment, the dose of dexamethasone 
was slowly tapered. Temozolomide could not be given 
to any patients, due to cost constraints. Overall survival 
was calculated using the Kaplan–Meier method. This 
study was approved by the Institutional Review Board 
of SKMCH and RC.
Results
The median age of our patients was 50 years (range 
20–71 years) with 44 (71%) males and 18 (29%) females. 
Patients’ demographic characteristics are shown in 
Table 1. Performance status according to the World 
Health Organisation criteria was ECOG-0 in 47 (76%) 
and ECOG-1 in 15 (24%) patients. 7 (11%) patients 
underwent GTR, 52 (83%) had subtotal resection and 
3 (5%) had biopsy only. Response assessment on MRI at 
3 months after HRT showed that 14 (22%) patients had 
regression, 21 (34%) had stable disease and 22 (35%) 
patients had progressive primary tumour. 5 (8%) 
patients were lost to follow-up. Radiation toxicity was 
not recorded formally. With a median follow-up of 
7.8 months, the median overall survival was 9 months. 
Patients with ECOG-0 showed a median survival of 
7 months as compared to 6 months for those with 
ECOG-1. Patients with stable or partial response showed 
a median overall survival of 8 months in comparison 
to 6 months for those with progressive disease. There 
was no significant association of median survival 
with the extent of surgery. A Cox multivariate model 
confirmed a significant correlation of age and response 
to radiotherapy with overall survival [Figures 1-3].
Discussion
Patients with GBM have a dismal prognosis. Surgery 
followed by chemoradiation and adjuvant temozolomide 
is considered the standard treatment.[6]
Table 1: Patient characteristics
Patient characteristics n (%)
Median age: 50 years (20‑71 years)





ECOG 0 47 (75.8)
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The usual dose of conventional radiotherapy for the 
treatment of GBM with 2.0 Gy/fraction is around 60 Gy.[10] 
Literature has not shown an improvement in overall 
survival by increasing the total dose >60 Gy.[10-12] Altered 
fractionation schemes also do not result in longer survival.
[10,13-16] In the studies on accelerated hyperfractionated 
radiotherapy, using three to four fractions per day, total 
doses of 36–50 Gy have been delivered in 2–3 weeks, 
without an increase in toxicity compared to conventional 
radiotherapy.[13,14]
Hypofractionation is defined as giving a dose per fraction 
>2.0 Gy with a reduced total number of fractions. 
Hypofractionation lowers the therapeutic ratio between 
the tumour and late responding normal tissues. Late 
normal tissue toxicity is of little clinical relevance in 
patients with GBM due to their short overall survival. 
GBM tumours have a rapid doubling time so that 
standard or hyperfractionated radiotherapy schedules 
can compromise the outcome due to rapid tumour 
repopulation.[15] The published data show that almost 
12–37.5% of patients show progression at the end of 
treatment. Hypofractionation provides a dual benefit: 
First, there is increased cell kill, and second, it reduces 
the accelerated repopulation of tumour cells.[15]
As calculated by the linear quadratic equation using 
an alpha/beta 3 Gy for late effects, the biologically 
effective dose (BED) of 48 Gy/16 fractions in terms of 
conventional fractionation is 57.6 Gy.[17] This is almost 
equivalent to the 60-Gy standard established by the 
Brain Tumour Study Group.[15] The safety of large dose 
fractionation with one fraction per day has also been 
documented in patients with GBM.[18-21] We found HRT 
to be medically well tolerated and a more convenient 
approach for our patients, as many of our patients came 
from remote areas. It is also a more resource-friendly 
radiation treatment schedule. The median survival of 
patients with GBM is measured in months rather than in 
years due to their shortened overall survival. Therefore, 
it is of paramount importance to decrease the duration 
of treatment and hospitalisation.[22,23] We have used a 
short radiation schedule with an overall treatment time 
of 3.5 weeks. The survival rates recorded in this study 
are comparable to those achieved with conventional 
radiotherapy schedules, without the use of concurrent 
or adjuvant chemotherapy. Trials where radiation is 
used as a monotherapy have shown survival of up to 
12 months. We could not assess toxicity in our study due 
to inadequate data present in our database. Other studies 
have suggested that important prognostic factors for GBM 
are age,[10,17,24,25] performance status[10,11,17,24] and extent of 
surgery.[10,17,24] In an analysis of 645 patients from three 
radiation therapy oncology group trials, age, Karnofsky 
performance status, extent of surgery and primary tumour 
site were identified as independent prognostic factors.[17] 
In this study, the median survival of patients with ECOG-
0 was almost 7 months compared to 6 months in patients 
with ECOG-1.
Figure 1: Overall survival of patients
Figure 2: Overall survival of patients stratified by the Eastern 
Cooperative Oncology Group performance status
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Limitations of this study
This study has several limitations. First, it was a 
retrospective review. Second, we were unable to 
collect data on radiation toxicity amongst our patients. 
Third, due to cost constraints, we were unable to offer 
temozolomide to our patients. However, this study offers 
some evidence that HRT might be appropriate for certain 
patient populations.
Conclusion
HRT alone is mainly used in elderly patients and those 
with poor performance status. However, it is a good 
alternative in good performance status patients when 
resources are limited. It is a resource-sparing treatment 
strategy with an acceptable overall survival.
Conflict of Interest
The authors declare that they have no conflict of interest.
References
1. Karim AB, van der Schueren E, Gonzalez DG, et al. 
Radiotherapy of malignant gliomas. In: Karim AB, Laws 
ER Jr., editors. Glioma. Principles and Practice in Neuro-
Oncology. Berlin: Springer Verlag; 1991. p. 121-4.
2. Greig NH, Ries LG, Yancik R, Rapoport SI. Increasing 
annual incidence of primary malignant brain tumors in the 
elderly. J Natl Cancer Inst 1990;82:1621-4.
3. Hess KR, Broglio KR, Bondy ML. Adult glioma 
incidence trends in the United States, 1977-2000. Cancer 
2004;101:2293-9.
4. Hoffman S, Propp JM, McCarthy BJ. Temporal trends in 
incidence of primary brain tumors in the United States, 
1985-1999. Neuro Oncol 2006;8:27-37.
5. Kristiansen K, Hagen S, Kollevold T, et al. Combined 
modality therapy of operated astrocytomas grade III and 
IV. Confirmation of the value of postoperative irradiation 
and lack of potentiation of bleomycin on survival time: 
A prospective multicenter trial of the Scandinavian 
Glioblastoma Study Group. Cancer 1981;47:649-52.
6. Walker MD, Alexander E Jr., Hunt WE, et al. Evaluation 
of BCNU and/or radiotherapy in the treatment of 
anaplastic gliomas. A cooperative clinical trial. J Neurosurg 
1978;49:333-43.
7. Grau JJ, Verger E. Radiotherapy of the brain in elderly 
patients. Pro Eur J Cancer 2000;36:443-7.
8. Iwamoto FM, Reiner AS, Panageas KS, et al. Patterns of care 
in elderly glioblastoma patients. Ann Neurol 2008;64:628-34.
9. Kita D, Ciernik IF, Vaccarella S, et al. Age as a predictive 
factor in glioblastomas: Population-based study. 
Neuroepidemiology 2009;33:17-22.
10. Tamura M, Nakamura M, Kunimine H, et al. Large dose 
fraction radiotherapy in the treatment of glioblastoma. 
J Neurooncol 1989;7:113-9.
11. Peschel RE, Wilson L, Haffty B, et al. The effect of 
advanced age on the efficacy of radiation therapy for early 
breast cancer, local prostate cancer and grade III-IV gliomas. 
Int J Radiat Oncol Biol Phys 1993;26:539-44.
12. Hernandez JC, Maruyama Y, Yaes R, et al. Accelerated 
fractionation radiotherapy for hospitalized glioblastoma 
multiforme patients with poor prognostic factors. 
J Neurooncol 1990;9:41-5.
13. Hercbergs AA, Tadmor R, Findler G, et al. Hypofractionated 
radiation therapy and concurrent cisplatin in malignant 
cerebral gliomas. Rapid palliation in low performance status 
patients. Cancer 1989;64:816-20.
14. Kaplan-Meier EL, Meier P. Nonparametric estimation from 
incomplete observations. J Am Stat Assoc 1958;53:457-81.
15. Hingorani M, Colley WP, Dixit S, et al. Hypofractionated 
radiotherapy for glioblastoma: Strategy for poor-risk 
patients or hope for the future? Br J Radiol 2012;85:e770-81.
16. Slotman BJ, Kralendonk JH, van Alphen HA, et al. 
Hypofractionated radiation therapy in patients with 
glioblastoma multiforme: Results of treatment and impact of 
prognostic factors. Int J Radiat Oncol Biol Phys 1996;34:895-8.
17. Fowler JF. The linear-quadratic formula and progress in 
fractionated radiotherapy. Br J Radiol 1989;62:679-94.
18. Villà S, Viñolas N, Verger E, et al. Efficacy of radiotherapy 
for malignant gliomas in elderly patients. Int J Radiat Oncol 
Biol Phys 1998;42:977-80.
19. Lantos PL, Bruner JM. Gliomatosis cerebr. In: Kleihues P, 
Cavenee WK, editors. Pathology and Genetics of Tumours 
of the Nervous System. Lyon: IARC Press; 2000. p. 92.
20. Thomas R, James N, Guerrero D, et al. Hypofractionated 
radiotherapy as palliative treatment in poor prognosis 
Figure 3: Overall survival of patients stratified by the extent 
of surgical resection
JOURNAL OF CANCER & ALLIED SPECIALTIES 5
ORIGINAL ARTICLE J Cancer Allied Spec 2015;1(2):3
patients with high grade glioma. Radiother Oncol 
1994;33:113-6.
21. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate 
analysis of 416 patients with glioblastoma multiforme: 
Prognosis, extent of resection, and survival. J Neurosurg 
2001;95:190-8.
22. Kleinberg L, Slick T, Enger C, et al. Short course 
radiotherapy is an appropriate option for most malignant 
glioma patients. Int J Radiat Oncol Biol Phys 1997;38:31-6.
23. Mohan DS, Suh JH, Phan JL, et al. Outcome in elderly 
patients undergoing definitive surgery and radiation therapy 
for supratentorial glioblastoma multiforme at a tertiary care 
institution. Int J Radiat Oncol Biol Phys 1998;42:981-7.
24. Halperin EC. Malignant gliomas in older adults with poor 
prognostic signs. Getting nowhere, and taking a long time 
to do it. Oncology (Williston Park) 1995;9:229-34.
25. Curran WJ Jr., Scott CB, Horton J, et al. Recursive 
partitioning analysis of prognostic factors in three Radiation 
Therapy Oncology Group malignant glioma trials. J Natl 
Cancer Inst 1993;85:704-10.
